ChemoCentryx Inc CCXI:NASDAQ

Last Price$25.53Cboe Previous Close - Real-Time Last Sale as of 4:00PM ET 1/26/22
Cboe Real-Time Quotes
Today's Change+0.07(0.27%)
Bid (Size)$25.77 (2)
Ask (Size)$26.11 (500)
Day Low / High$24.85 - 26.97
Volume2.7 K

View Biotechnology IndustryPeer Comparison as of 01/26/2022


ChemoCentryx Inc ( NASDAQ )

Price: $25.53
Change: +0.07 (0.27%)
Volume: 2.7 K
4:00PM ET 1/26/2022

Global Blood Therapeutics Inc ( NASDAQ )

Price: $27.42
Change: +0.91 (3.43%)
Volume: 106.00
9:37AM ET 1/27/2022

Agios Pharmaceuticals Inc ( NASDAQ )

Price: $31.11
Change: +0.11 (0.35%)
Volume: 438.3 K
9:43AM ET 1/27/2022

Ligand Pharmaceuticals Inc ( NASDAQ )

Price: $113.76
Change: +0.08 (0.07%)
Volume: 163.0 K
4:00PM ET 1/26/2022

Veracyte Inc ( NASDAQ )

Price: $27.90
Change: +0.84 (3.10%)
Volume: 1.0 M
9:41AM ET 1/27/2022

Read more news Recent News

ChemoCentryx Secures EU Approval for Vasculitis Treatment
9:48AM ET 1/19/2022 MT Newswires

ChemoCentryx (CCXI) said Wednesday that the European Union has approved Tavneos for the treatment of patients with diseases associated with blood vessel...

Insider Sell: Chemocentryx
6:26AM ET 12/22/2021 MT Newswires

James L Tyree, Director, on December 17, 2021, sold 37,500 shares in Chemocentryx (CCXI) for $1,313,165. Following the Form 4 filing with the SEC, Tyree...

ChemoCentryx Says European Medicines Agency Recommends Tavneos Marketing Authorization
10:44AM ET 11/12/2021 MT Newswires

ChemoCentryx (CCXI) said Friday the European Medicines Agency issued a positive opinion, recommending marketing authorization for its Tavneos drug. Tavneos...

ChemoCentryx Narrows Q3 Loss on Rising Revenue; Stock Rises
10:46AM ET 11/10/2021 MT Newswires

ChemoCentryx (CCXI) reported a Q3 net loss of $0.32 per share, compared with a $0.35 loss a year ago. Analysts polled by Capital IQ expected a loss of...

View all Commentary and Analysis

ChemoCentryx (CCXI) Presents At J.P. Morgan 40th Annual Healthcare Conference - Slideshow
2:38PM ET 1/12/2022 Seeking Alpha

Our First Look At InflaRx
4:56PM ET 12/29/2021 Seeking Alpha

Checking In On ChemoCentryx
9:38PM ET 12/14/2021 Seeking Alpha

IBB And XBI: 4 Reasons To Buy Biotech Stocks Ahead Of 2022
8:33AM ET 12/06/2021 Seeking Alpha

Company Profile

Business DescriptionChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. View company web site for more details
Address835 Industrial Road
San Carlos, California 94070
Number of Employees76
Recent SEC Filing01/25/20224
Chairman, President & Chief Executive OfficerThomas J. Schall
Chief Operating Officer & Executive Vice PresidentTausif Butt
Chief Financial Officer, Secretary & DirectorSusan M. Kanaya
Chief Medical Officer, Executive Director & EVPRita I. Jain

Company Highlights

Price Open$25.96
Previous Close$25.46
52 Week Range$9.53 - 70.29
Market Capitalization$1.8 B
Shares Outstanding69.9 M
SectorHealth Technology
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.74
Beta vs. S&P 500N/A
Revenue$42.9 M
Net Profit Margin-355.13%
Return on Equity-34.78%

Analyst Ratings as of 10/08/2021

Consensus RecommendationConsensus Icon
Powered by Factset